Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR oncogenic variants status confers therapeutic sensitivity to Erlotinib, Ramucirumab in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.
This statement is based on a regulatory approval from the European Medicines Agency:
Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.